Percutaneous Systems Inc. (PercSys)
HCID Member | Medical Devices & Tech  Advamed Member
3260 Hillview Avenue, Suite 100
Palo Alto, CA 94304-1201 USA
phone: 650.493.4200
fax: 650.493.4201
Symbol Private
Founded 0
Employees
www.percsys.com
Research Sector Medical Devices & Tech
Summary Description
Instruments that make urologic and endoscopic procedures easier, less traumatic and more effective
Management
Robert Behl - CEO, Craig Ball - VP Marketing
Keywords
Urologic, Urology, kidney stones, ureteral stones, stone management, endoscopic devices, catheters, advamed

Comment | Printable Version | Jul. 18, 2008
If you work for Percutaneous Systems Inc. (PercSys) and want to update this profile, click here

Description
The mission of Percutaneous Systems, Inc. (PercSys) is to develop devices that make urologic and endoscopic procedures easier, less traumatic and more effective therapeutically. While its current devices influence outcomes of procedures performed in the operating room, devices in the pipeline will help move procedures from the hospital into the office environment.
Products / Services
In June, 2007, the company released the 7mm PercSys Accordion Stone Management Device, which was ideal for use in stone procedures in the lower and middle ureter. PercSys added a 10mm version of the device to the Accordion family in March, 2008. This larger device was designed to occlude the upper ureter in order to prevent stone/fragment migration in both ureteroscopic and percutaneous nephrolithotomy (PCNL) stone procedures.
Technology / Differentiation
The PercSys Accordion Stone Management Device can be used to entrap and remove stones and other foreign objects from the ureter. The device combines the attributes of multiple endoscopic stone management tools into a single device. The Accordion device tracks past the stone like a guidewire and can be monitored with fluoroscopic or endoscopic imaging. Once formed, the device's film occlusion conforms to and fills the ureter and is designed to prevent retrograde migration of stone fragments. During stone fragmentation, the Accordion device facilitates distal rinsing of smaller fragments in order to keep the field of view clear. Following fragmentation, the device can sweep larger fragments into the bladder or a ureteral access sheath, thereby eliminating the tedious and often time-consuming serial basketing of individual fragments. These benefits combine to simplify endoscopic lithotripsy procedures.
Market / Customers
Approximately 5 percent of Americans will be affected by urinary stones at some point in their life. The incidence of a kidney stone is among the most painful and prevalent of urologic disorders. If a stone becomes large enough, it can block or otherwise create pressure, pain, and infection in the kidney or ureter, the duct that carries urine from the kidneys to the bladder. Many patients experiencing urinary stones can be managed with medications and large amounts of fluids. In patients with larger stones, external or minimally invasive surgical intervention may be required.
Strategy
PercSys is conducting randomized, prospective research into the potential to reduce both the operative time and disposable instrument use facilitated by the adoption of the Accordion device in ureteroscopic stone procedures. In addition, the company is investigating the Accordion device's capability to influence the effectiveness and outcomes of extracorporeal shock wave lithotripsy (ESWL) of stones in the ureter. Finally, through both internal development and outside collaboration, PercSys has identified a portfolio of additional products that have the capability both to improve upon significantly the current stone treatment options and eventually to supplant the outdated patient management paradigm for stone disease. Through these efforts, PercSys seeks to become a leading provider of urological devices for the management of kidney/ureteral stones.
Status
PercSys is in the midst of driving a five-year series of unique product introductions for urology. The company's first product was introduced in mid-2007 at the American Urological Association (AUA) meeting and the second product release coincided with the AUA's 2008 meeting. PercSys currently is in market development in limited geographies and plans a full-scale commercial launch later in 2008.


2008-10-12-2772